嗅神经母细胞瘤初诊及疾病复发时的淋巴结转移:患病率数据及影响区域控制的变量的系统综述与比例荟萃分析
该系统综述与比例荟萃分析基于PubMed、Web of Science和Scopus,纳入18篇文章,研究原发、未治疗嗅神经母细胞瘤初诊时及随访中颈部淋巴结转移的患病率,并回顾治疗方式、区域失败风险因素及按淋巴结状态的生存结局。初诊时淋巴结转移的合并比例为11.5%,与未接受择区颈部治疗的cN0患者随访中出现淋巴结转移的12.3%相当;后者中多数为Kadish C期肿瘤(85.5%)。
要点
- 初诊时淋巴结转移合并比例为11.5%。
- cN0未接受择区颈部治疗者随访淋巴结转移比例为12.3%。
- 晚期转移者中Kadish C期占85.5%。
核心结论
- 颈部受累在初诊时及cN0嗅神经母细胞瘤随访中均常见。
- cN0且Kadish C期肿瘤未接受择区颈部治疗的患者发生晚期淋巴结转移的风险最高。
- 作者认为,对选定患者应鼓励行择区cN0颈部治疗以提高区域控制。
研究设计与样本
- 遵循PRISMA指南的系统综述与比例荟萃分析,检索PubMed、Web of Science和Scopus,纳入18篇文章。
主要发现
- 初诊时淋巴结转移的合并比例为11.5%。
- cN0患者未接受择区颈部治疗随访中出现淋巴结转移的比例为12.3%。
- 上述随访中出现淋巴结转移者中,Kadish C期肿瘤占85.5%。
临床怎么用
- 作者认为,对选定患者应鼓励行择区cN0颈部治疗以提高区域控制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aim of this study is to investigate the prevalence of cervical nodal metastasis at presentation and as disease relapse in primary, treatment-naive olfactory neuroblastoma (ONB), and to review treatment modalities, risk factors for regional failure and survival outcomes according to nodal status. METHODS: A systematic review and proportion meta-analysis were conducted following PRISMA guidelines based on PubMed, Web of Science, and Scopus. RESULTS: Eighteen articles were examined. The pooled proportion of patients with nodal metastasis at presentation (11.5%) was comparable to that of cN0 patients not receiving elective neck treatment developing nodal metastasis during follow-up (12.3%). Of the latter, most were Kadish stage C tumors (85.5%). CONCLUSIONS: Cervical involvement is common both at presentation and during follow-up of cN0 ONB. The highest risk of developing late nodal metastasis is seen in cN0 patients with Kadish stage C tumors not receiving elective neck treatment. Elective cN0 neck treatment should be encouraged in selected patients to increase regional control.
引用
- Tomasoni M, Marazzi E, Rampinelli V, et al. Lymph node metastasis from olfactory neuroblastoma at presentation and as disease relapse: A systematic review and proportion meta-analysis of prevalence data and variables influencing regional control. Head Neck. 2023. PMID: 36995898. doi:10.1002/hed.27361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。